SCHEMBL23577752

SCHEMBL23577752

CCOC(=O)c1cc2c(cc1NC(=O)OC(C)(C)C)oc(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 2/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ ALOX15 P16050 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ GALR2 O43603 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ CCR6 P51684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30184079 1.00 LMNA (0.43) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL23578095 0.85 ALDH1A1 (0.43) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL30034889 0.85 ALDH1A1 (0.43) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL23590999 0.80 SMN1; SMN2 (0.40) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL30036541 0.78 KMT2A (0.38) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL23577722 0.78 KMT2A (0.38) LMNATP53SMN1; SMN2MAPTALDH1A1
SCHEMBL30183695 0.76 LMNA (0.47) LMNATP53MAPTALDH1A1KDM4E
SCHEMBL23577635 0.76 LMNA (0.47) LMNATP53ALDH1A1KDM4ECA12
SCHEMBL23577953 0.76 LMNA (0.47) LMNATP53MAPTALDH1A1KDM4E
SCHEMBL30183917 0.76 LMNA (0.47) LMNATP53ALDH1A1KDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 — — EP disclosed
US-20230119316-A1 Substituted Tricyclic Compounds LUPIN LIMITED (IN) 2023-04-20 — — US disclosed
EP-4081521-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-11-02 — — EP disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119316-A1 Substituted Tricyclic Compounds SOS1, RSU1, KSR1 LMNA 1729/4885TP53 46/4885SMN1; SMN2 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback